CG3.BE: Summary for CELGENE CORP. DL-,01 - Yahoo Finance

UK Markets close in 3 hrs 39 mins


Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
114.40+1.21 (+1.07%)
As of 8:08AM CEST. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous close113.19
Bid115.05 x
Ask115.82 x
Day's range114.40 - 114.40
52-week range109.75 - 118.68
Avg. volume17
Market cap
PE ratio (TTM)N/A
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • The Wall Street Journal10 hours ago

    [$$] Aquinnah Pharmaceuticals Taps Pfizer, AbbVie for $10 Million

    A trio of pharmaceutical companies is financing an effort by Aquinnah Pharmaceuticals Inc. to use a new approach to tackling neurological diseases that have long frustrated drugmakers.

  • American City Business Journals2 days ago

    Celgene research leader Dr. Rupert Vessey joins Juno board

    Juno Therapeutics Inc. has added Celgene Corp. President of Research and Early Development Dr. Rupert Vessey to the Seattle-based biotech's board. Vessey will serve as as Celgene's designated appointee to Juno's board, replacing Dr. Tom Daniel, who retired last summer but will remain on the board as an independent director. Juno (JUNO) inked a $1 billion collaboration with Celegene in 2015.

  • TheStreet.com3 days ago

    Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

    The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.